Company Views Participation at Forefront of Emerging Trends in Nanomedicine as Important to Ongoing Strategy for Success
CAMBRIDGE, MA -- (Marketwired) -- 07/23/13 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to advise that co-founding and inventing scientist, Dr. Rutledge Ellis-Behnke, delivered a lecture titled "The Spider Effect, how the Immune System in the Brain can be Measured and Modulated with Nanotechnology" at the 6th annual European Foundation for Clinical Nanomedicine (CLINAM) Summit in Basel, Switzerland.
The focus of this year's CLINAM Summit was 'Nanomedicine & Targeted Medicine -- the paradigm of precise, highly effective and safe medicine with subtle influence for the benefit of patients and mankind.' Beat Löffler, Executive Director of CLINAM, said the goal of the 2013 Summit was "to bring together the most skilled people in an effort to help to shape this scientific field and thereby push the boundaries of cutting-edge Nanomedicine and Targeted Medicine."
Ellis-Behnke, a founding board member of the International Society of Nanomedicine, discussed the groundbreaking system he designed to categorize the activation status of microglia using morphological attributes. "The work represents a new measurement system for inflammation that assigns an objective number to the level of inflammation and thus can be used as a diagnostic to treat and measure the response," he said.
Ellis-Behnke noted, "Inflammation is often only treated for two weeks. However, our work indicates that inflammation can last far longer than that before returning to a resting state, suggesting that inflammation needs to be treated far longer than was once thought. In order to modulate these responses, it is important to control the leakage of blood within and between tissue components as well as in the local environment. This can be accomplished with novel materials."
Dr. Ellis-Behnke was instrumental in discovering the hemostatic and other barrier properties of self-assembling peptides that could make future surgery and interventional care faster and safer. He proposed the development and commercialization of Arch Therapeutics' flagship product candidate known as AC5™.
Arch Therapeutics CEO, Dr. Terrence Norchi further comments, "Dr. Ellis-Behnke is at the forefront of emerging trends in nanomedicine and the advice he provides our Company continues to be of great importance. He is the lead inventor on the intellectual property exclusively licensed by Arch Therapeutics from the Massachusetts Institute of Technology and his work offers strategic insights that shape our future and the roadmap for our success."
Additional details regarding Arch Therapeutics, Inc., its business, agreements and related matters are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission ("SEC"), and are available at the SEC's website at www.sec.gov. For more information, visit our website at www.archtherapeutics.com.
About Arch Therapeutics, Inc. (OTCQB: ARTH)
Arch Therapeutics, Inc. (OTCQB: ARTH) is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch's goal is to develop and commercialize products based on our innovative technology platform that make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate known as AC5™ is being designed to elegantly achieve hemostasis in minimally invasive and open surgical procedures. Find out more at www.archtherapeutics.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.
On Behalf of the Board,
Terrence W. Norchi, MD.
Arch Therapeutics, Inc.
Contact:
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com
Source: Arch Therapeutics, Inc.